HealthShares Emerging Cancer
exchange-traded fund was Friday's best performer.
soared 164.2% after the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating prostate cancer. The ETF was jumping $2.40, or 10.7%, to $24.82.
Other biotech and health care ETFs were gaining ground. The
PowerShares FTSE RAFI Health Care
was adding 4% to $50.98. The
First Trust Amex Biotechnology Index
was gaining 1% to $23.84. The
SPDR S&P Biotech
was up 0.9% at $48.22.
On the other hand, the
B2B Internet HOLDRs
ETF was lower, as holdings
were shedding 1.5%. The ETF was off 4 cents, or 1.8%, to $2.14.
Bundled securities tracking the energy sector were also among the losers of the day, as oil prices retraced some of its 6% gain for the week. The front-month May crude contract was recently losing 26 cents to $65.77 a barrel.
Energy Select Sector SPDR
ETF was recently down 1.4% to $60.25. The
iShares Dow Jones U.S. Oil Equipment Index
ETF was off 1.3% to $48.14. The
PowerShares Dynamic Energy Exploration
ETF was losing 1.2% to $20.30. The
Oil Services HOLDRs
ETF eased 1.1% to $146.35.